New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

Core Insights - Novartis will present data from 60 abstracts at the 2025 ASCO Annual Meeting and EHA 2025 Congress, showcasing advancements in oncology and hematology [1][2] - The company emphasizes its leadership in oncology with key products such as Kisqali, Pluvicto, Scemblix, and Fabhalta, and aims to improve patient outcomes through partnerships and innovative therapies [2][3] ASCO Highlights - Key abstracts include: - Kisqali's efficacy and safety in various settings, including a real-world analysis in Black patients with early breast cancer [4][5] - Pluvicto's clinical outcomes in metastatic castration-resistant prostate cancer [6] - Scemblix's results in chronic myeloid leukemia, demonstrating its efficacy compared to other treatments [6] EHA Highlights - Key abstracts include: - Fabhalta's efficacy in patients with paroxysmal nocturnal hemoglobinuria [7] - Scemblix's superior tolerability compared to nilotinib in chronic myeloid leukemia [8] - Pelabresib's long-term efficacy in myelofibrosis patients [8] Company Strategy - Novartis focuses on improving the lives of cancer patients through innovative medicines and partnerships with advocacy groups, emphasizing early detection and patient-centered care [9][10]